VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

COSTEM 2022 | COSTEM AML highlights: SCT & MRD status, sorafenib maintenance & gilteritinib in FLT3+ AML

Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, shares some of the highlights in acute myeloid leukemia (AML) from the 2022 COSTEM meeting, discussing the role of CAR-T therapy and stem cell transplantation (SCT) in AML. The FIGARO trial (EudraCT: 2012-005538-12) demonstrated a higher relapse risk for patients who are MRD-positive receiving conditioning treatment pre-transplant, and the PRO-DLI trial (NCT02856464) is currently assessing prophylactic treatment in patients receiving transplantation. Prof. Craddock additionally comments on the role of maintenance therapy with sorafenib in AML, and talks on the Phase III MORPHO trial (NCT02997202) of gilteritinib in FLT3-positive AML. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter